Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Myeloma (US) 2016

Product Code:
Publication Date:
September 2016

Survey Results: Doctors say 5 major brands are losing market share due to prescription barriers

We surveyed 100 US oncologists and haematologists to find out how market barriers affect the way they prescribe 9 myeloma drugs. The results show that 5 of those treatments lose market share overall while the other 4 make small net gains.

Find out why, and learn what your brand can do to regain lost share, in Market Access Impact: Myeloma (US).
Request sample pages

The report covers major brands from Amgen, BMS/AbbVie, Celgene, Janssen Biotech, Novartis, and Takeda. You’ll discover which brands see the biggest gains and losses from 7 different market barriers, which barriers help and hurt your brand the most, and which competitors you take share from and lose it to.

Not your market? Click here to see the EU5 report 

Request sample pages

Top Takeaways

  • Most brands are widely prescribed: More than 60% of the doctors surveyed prescribe 7 of the 9 brands covered, and at least 90% of them prescribe the top 3 brands.
  • Only two brands see significant share gains: While the four most prescribed brands all see net gains because of market barriers, two of them gain less than 0.5%.
  • Cost is the top barrier, but not all brands are affected equally: Cost affects more prescriptions than any other barrier, but more doctors experience cost barriers with 4 of the surveyed brands.
  • Eliminating barriers would shake up the bottom of the market: Moving the 6th place band into 5th place and the 8th place brand into 7th place. The top of the market would not be affected.
  • Most barriers have the greatest effect on two brands: more doctors experience most barriers with these brands than with others.
  • One brand has a big perception problem: 30% of the doctors surveyed would not consider prescribing this brand. For most of the other surveyed brands, that number is 2% or less.

Insight into 9 Major Myeloma Drugs

  • Darzalex (daratumumab; Janssen Biotech)
  • Empliciti (elotuzumab; BMS/AbbVie)
  • Farydak (panobinostat; Novartis)
  • Kyprolis (carfilzomib; Amgen)
  • Ninarlo (ixazomib; Takeda)
  • Pomalyst (pomalidomide; Celgene)
  • Revlimid (lenalidomide; Celgene)
  • Thalomid (thalidomide; Celgene)
  • Velcade (bortezomib; Takeda)

Exploring Important Market Access Issues

Market Access Impact: Myeloma explores key issues affecting Myeloma drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US medical oncologists and haematologists, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with multiple myeloma in total in the last month

We conducted the survey between September 5th and 8th, 2016.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved